The GLP-1 Budget Bomb: How to Defuse It

TJ Bullock | January 28th, 2026

IN PLAIN BENEFITS
January 28, 2026

Let's talk about the elephant in the pharmacy: GLP-1 drugs.

Ozempic. Wegovy. Mounjaro. Zepbound. You've seen them everywhere , on TikTok, in the news, probably in your own break room conversations. These medications have taken the world by storm, and for good reason. They work. People are losing weight, managing diabetes, and feeling better than they have in years.

But here's the thing nobody wants to say out loud:

Your health plan might not survive the GLP-1 revolution.

That sounds dramatic. It's not. GLP-1 medications represent one of the most significant budget threats employers have faced in decades. And if you're not paying attention, this category alone could blow up your benefits budget.

Let's break down what's actually happening , and more importantly, what you can do about it.

---

1️⃣ THE HYPE VS. THE COST

First, let's acknowledge reality: these drugs are genuinely effective. We're not talking about another fad diet pill. GLP-1 medications help people lose significant weight and manage Type 2 diabetes in ways we haven't seen before. The clinical results are impressive.

But impressive results come with an impressive price tag.

Here's the math that should keep you up at night:

• Individual prescriptions often exceed $1,000 per month , sometimes closer to $1,500
• GLP-1s account for only about 1% of all prescriptions
• Yet they represent over 8% of total prescription drug spending before rebates

Read that again. One percent of prescriptions. Eight percent of the budget.

Between 2019 and 2024, gross Medicaid spending on GLP-1s increased ninefold , from roughly $1 billion to almost $9 billion. And that's just Medicaid. Add in commercial plans, and you're looking at a tsunami of pharmacy spend that shows no signs of slowing down.

The hype is real. The cost is real-er.

---

2️⃣ THE "FOREVER" FACTOR

Here's the part that doesn't make the magazine covers: GLP-1s aren't a one-time fix.

This isn't like getting a surgery and moving on with your life. Studies show that when people stop taking GLP-1 medications, most of the weight comes back. That means these drugs aren't a treatment , they're a long-term commitment.

For employers, that changes everything.

Think about it:

• An employee starts Ozempic this year at $1,200/month
• They get great results and want to stay on it
• That's $14,400 per year, per person, potentially for life

Now multiply that by 10 employees. Or 50. Or 200.

The "forever factor" turns a pharmacy expense into a structural budget problem. It's not a one-year spike you can absorb. It's a permanent line item that grows as more employees (and their dependents) start these medications.

States are already feeling the pressure. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity treatment. Pennsylvania just eliminated Medicaid coverage for weight loss entirely. When government programs start cutting coverage, you know the costs are serious.

---

3️⃣ CLINICAL MANAGEMENT: RIGHT PEOPLE, RIGHT DRUG

So what do you do? You can't just say "no GLP-1s" and call it a day. These medications genuinely help people with serious health conditions. Blocking access entirely isn't just bad for morale , it's bad medicine.

The answer is clinical management.

Not everyone who wants a GLP-1 should be on one. And not everyone on a GLP-1 should be on the most expensive version available. Clinical management means putting guardrails in place so the right people get the right drug at the right time.

Here's what that looks like in practice:

Prior authorization with teeth. Make sure there's a real clinical review before approval , not just a rubber stamp. Is this person a candidate based on BMI and comorbidities? Have they tried lifestyle interventions first? Are there contraindications?

Step therapy requirements. Not everyone needs to start with the brand-name injectable at top dollar. There may be lower-cost options to try first, including older diabetes medications that have some GLP-1-like effects.

Ongoing monitoring. Is the medication actually working? If someone has been on a GLP-1 for a year with no meaningful results, why are we still paying for it? Build in checkpoints.

Specialty pharmacy steering. Where the medication is filled matters. Specialty pharmacies often have better pricing and clinical support than retail chains.

The goal isn't to deny care. The goal is to make sure every dollar spent is actually improving someone's health , not just checking a box.

---

4️⃣ DIRECT SOURCING: SKIP THE MARKUP

Here's a secret the pharmacy supply chain doesn't want you to know: you're probably paying way more than you need to.

The traditional path looks like this:

Manufacturer → Wholesaler → Pharmacy → PBM → Your Plan → Employee

Every step in that chain takes a cut. By the time the drug reaches your employee, the price has been marked up, rebated, spread-priced, and fee'd to death.

Direct sourcing flips the script.

Some employers are now working with programs that connect directly with manufacturers or use alternative fulfillment channels that bypass the traditional PBM markup. The Trump administration recently announced a direct-to-consumer platform called TrumpRx that offers GLP-1 injections at approximately $350 per month , a significant discount from the $1,000+ retail price.

Starting in April 2026, Medicare will cover GLP-1s for beneficiaries with obesity at $245 per month with copays capped at $50. That's the government using its purchasing power to negotiate better rates.

Why can't employers do the same?

The answer is: you can. You just have to ask.

Here are some direct sourcing strategies to explore:

Manufacturer patient assistance programs. Eli Lilly and Novo Nordisk both have programs that can reduce costs for qualifying patients. Make sure your employees know about them.

International pharmacy options. In some cases, the same medications are available at a fraction of the U.S. cost through licensed international pharmacies. This isn't for everyone, but it's worth understanding the landscape.

Compounding pharmacies. Compounded versions of semaglutide (the active ingredient in Ozempic and Wegovy) have been available at lower prices, though FDA guidance is evolving here. Work with a knowledgeable advisor.

Oral formulations. The first oral GLP-1 pill received FDA approval in December 2025 with introductory pricing of $149 per month for the lowest dose. Pills are generally cheaper to manufacture and distribute than injections. Watch this space.

---

5️⃣ THE REBATE REALITY CHECK

One more thing to understand: rebates are not a solution.

Yes, rebates currently account for approximately 40% of the cost of leading GLP-1 drugs. That sounds great until you realize two things:

1. Rebates often go to the PBM, not directly back to your plan
2. High list prices are sometimes inflated specifically to generate bigger rebates

If your PBM is keeping a chunk of those rebates (or using "spread pricing" to pocket the difference), your "40% savings" might actually be 15% savings for you and 25% profit for them.

Ask your broker to run a rebate transparency analysis. Know exactly where those dollars are going.

---

The Bottom Line

GLP-1 medications are here to stay. The demand is only going to grow. Pretending this isn't happening is not a strategy.

But neither is panic.

The employers who win here will be the ones who:

• Understand the true cost (not just the list price)
• Implement smart clinical management (right people, right drug)
• Explore direct sourcing options (skip the middlemen)
• Demand transparency from their PBM (follow the rebates)

This is exactly the kind of challenge that separates order-taker brokers from true advisors. If your broker hasn't brought you a GLP-1 strategy yet, it's time to ask why.

Need help defusing your GLP-1 budget bomb? Let's talk.

MAKING COMPLICATED SIMPLE.

---